Cancer Stem Cell News Volume 3.43 | Nov 5 2014

    0
    12

    Cancer Stem Cell News 3.43 November 5, 2014

    Cancer Stem Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  CSCN on Twitter

     
    TOP STORY
    CD95 and CD95L Promote and Protect Cancer Stem Cells
    Researchers report that stimulation of CD95 on cancer cells or reducing miR-200c levels increases the number of cancer stem cells (CSCs), which are more sensitive to induction of death induced by CD95R/L elimination than non-CSC, while becoming less sensitive to CD95-mediated apoptosis. [Nat Commun] Abstract
    Learn to Enumerate Mammospheres & Tumorspheres Cultured in MammoCult: Watch Procedure Now

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    BID Mediates Selective Killing of APC-Deficient Cells in Intestinal Tumor Suppression by Nonsteroidal Antiinflammatory Drugs
    Scientists found that the extrinsic apoptotic pathway and the BH3 interacting-domain death agonist (BID) are activated in adenomas from nonsteroidal antiinflammatory drug (NSAID)-treated patients. Loss of BID abolishes NSAID-mediated tumor suppression, survival benefit, and apoptosis in tumor-initiating stem cells in adenomatous polyposis coli (APC)Min/+ mice. [Proc Natl Acad Sci USA] Abstract | Press Release

    ISG15 Is a Critical Microenvironmental Factor for Pancreatic Cancer Stem Cells
    Scientists show that tumor-associated macrophages secrete the interferon-stimulated factor ISG15 which enhances cancer stem cell phenotypes in pancreatic ductal adenocarcinoma in vitro and in vivo. [Cancer Res] Abstract

    Targeting of miR-34a-NOTCH1 Axis Reduced Breast Cancer Stemness and Chemoresistance
    Researchers found that primary and mature microRNA-34a (miR-34a) were suppressed by treatment with p53 RNAi or the dominant negative p53 mutant in MCF7 cells. Ectopic miR-34a expression reduced cancer stem cell properties and increased sensitivity to doxorubicin treatment, by directly targeting NOTCH1. [Cancer Res] Abstract

    Notch3 Interactome Analysis Identified WWP2 as a Negative Regulator of Notch3 Signaling in Ovarian Cancer
    Ectopic expression of WWP2 decreased tumor development in a mouse xenograft model and suppressed the Notch3-induced phenotypes including increase in cancer stem cell-like cell population and platinum resistance. [PLoS Genet] Full Article

    TLX Activates MMP-2, Promotes Self-Renewal of Tumor Spheres in Neuroblastoma and Correlates with Poor Patient Survival
    The authors show that TLX (Drosophila tailless homolog) is essential for the formation of tumor spheres in three different neuroblastoma cell lines, when grown in neural stem cell media. They demonstrate that the knock down of TLX in IMR-32 cells diminishes its tumor sphere-forming capacity. [Cell Death Dis] Full Article

    Towards Elucidating the Connection between Epithelial-Mesenchymal Transitions and Stemness
    Incorporating the activation of OCT4 by LIN28, the authors found that the hybrid epithelial/mesenchymal (E/M) phenotype has high likelihood to gain stemness. Combining the LIN28/let-7 regulation by NF-κB and c-MYC, they found that NF-κB, but not c-MYC, elevates the likelihood of E/M phenotype to gain stemness. [J R Soc Interface] Abstract | Press Release

    Myelin-Forming Cell-Specific Cadherin-19 Is a Marker for Minimally Infiltrative Glioblastoma Stem-Like Cells
    Current molecular identifiers of glioblastoma stem-like cells (GSCs) are scarce and controversial. Scientists describe differential cell-surface gene expression profiling to identify GSC-specific markers. [J Neurosurg] Abstract

    Epigenetic Regulation of CD271, a Potential Cancer Stem Cell Marker Associated with Chemoresistance and Metastatic Capacity
    Investigators aimed to identify esophageal squamous cell carcinoma (ESCC) stem-like cells, the epigenetic mechanism and identify novel biomarkers for targeting ESCC cancer stem cells. [Oncol Rep] Abstract

    [Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™

     
    REVIEWS
    Recent Advances in Ginseng as Cancer Therapeutics: A Functional and Mechanistic Overview
    This review covers the mechanisms of action of ginsenosides and their metabolites, which can modulate signaling pathways associated with inflammation, oxidative stress, angiogenesis, metastasis, and stem/progenitor-like properties of cancer cells. [Nat Prod Rep] Abstract

    Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

     
    INDUSTRY NEWS
    OncoMed Pharmaceuticals Granted Anti-DLL4/Anti-VEGF Bispecific Antibody Patent in the U.S.
    OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells, has been granted a new patent in the United States for OncoMed’s anti-DLL4/anti-VEGF bispecific antibody and use of the bispecific antibody in the treatment of cancer. [OncoMed Pharmaceuticals, Inc.]
    Press Release

    BerGenBio Announces First Patient Dosed in BGB324 AML Trial
    BerGenBio AS announced that the first patient has been dosed in its multi-center Phase Ib trial of BGB324, a selective inhibitor of Axl, in patients with acute myeloid leukemia (AML). [BerGenBio AS] Press Release

    From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW Advances in Cancer Immunotherapy
    December 5, 2014
    Tampa, Florida

    NEW Cell & Gene Therapy Forum 2015
    January 26-28, 2015
    Washington DC, United States

    Visit our events page to see a complete list of events in the cancer stem cell community.

     
    JOB OPPORTUNITIES
    NEW Postdoctoral Fellow – Energy Metabolism and Nutrient Sensing in Cancer Development and Stem Cells (MD Anderson Cancer Center)

    NEW Postdoctoral Fellow – Cancer Biology (Lund University)

    Postdoctoral Position – Intestinal Stem Cell Biology and Gastrointestinal Malignancies (Albert Einstein College of Medicine of Yeshiva University)

    PhD Student Position – Cancer Biology (Queen Mary University of London)

    Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

    Postdoctoral Fellow – Gene Regulation in Breast Cancer/Stem Cell Biology (UC College of Medicine)

    Postdoctoral Position – Leukemic Stem Cells (BC Cancer Agency)

    Assistant or Associate Professor – Cancer Biology (University of Pennsylvania)

    Faculty Positions – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

    Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

    Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

    Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us